Degranulation

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Retrieved on: 
화요일, 4월 9, 2024
HER2, CD8, Phosphorylation, Survival, Cholangiocarcinoma, Immunotherapy, RECIST, Oncology, MAST, Patient, City, Degranulation, ASX, ADCC, Cancer, Hope, Overalls, Pembrolizumab, PRS, AACR, SPECT, Vaccination, Melanoma, Recurrence, PD-L1, IMU, Medical imaging

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.

Key Points: 
  • Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.
  • SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
  • HER-Vaxx induced HER2-specific antibodies able to mediate antibody-dependent cell cytotoxicity (ADCC) and inhibit intracellular HER2 phosphorylation and correlated with tumour reduction.
  • The HER-Vaxx induced HER2-specific antibodies demonstrate a similar mechanism of action to HERCEPTINâ validating B cell immunotherapy as an alternative anti-cancer agent to monoclonal antibodies.

AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders including Alzheimer's Disease

Retrieved on: 
월요일, 3월 8, 2021
Branches of biology, Biology, Cell biology, Masitinib, Mast cell, Membrane channel, Degranulation, Bone marrow

This review article [1] examines hemichannels and their contribution to mast cell degranulation in Alzheimers disease.

Key Points: 
  • This review article [1] examines hemichannels and their contribution to mast cell degranulation in Alzheimers disease.
  • Treatment with masitinib was shown to totally prevent the amyloid-induced hemichannel-dependent mast cell activity in bone marrow-derived mast cells and brain mast cells.
  • This research supports results from the phase 2B/3 study, AB09004, that evaluated oral masitinib in patients with mild and moderate Alzheimers disease.
  • AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq.

Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020

Retrieved on: 
수요일, 5월 6, 2020
Branches of biology, Biology, Cell biology, Tyrosine kinase receptors, Immunology, Granulocytes, Glycoproteins, Mast cell, Receptor tyrosine kinase, Degranulation, Tyrosine kinase, Antibody

CDX-0159 is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity.

Key Points: 
  • CDX-0159 is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity.
  • The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells.
  • In certain inflammatory diseases, such as chronic urticarias, mast cell degranulation plays a central role in the onset and progression of the disease.
  • You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.